A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase | Zendy

Regina El Dib | Zendy

Open Access

A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase

Author(s) -

Regina El Dib

Publication year - 2009

Publication title -

biologics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.948

H-Index - 38

eISSN - 1177-5491

pISSN - 1177-5475

DOI - 10.2147/btt.2009.3580

Subject(s) - enzyme replacement therapy , mucopolysaccharidosis , medicine , scielo , intensive care medicine , quality of life (healthcare) , medline , placebo , pediatrics , physical therapy , pathology , alternative medicine , biology , disease , biochemistry , nursing

Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome) is an autosomal recessive lysosomal storage disorder, characterized primarily by skeletal dysplasia and joint contracture. It is caused by a deficiency of N-acetylgalactosamine-4-sulfatase (arylsulfatase B), for which a recombinant formulation (galsulfase) is available as replacement therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research